Trial reportClinical endocrinology2014
Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.
Trial report in Clinical endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.Hormone research in paediatrics · 2019Guideline
- Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.Journal of the Endocrine Society · 2026Article
- Optimization of dosing regimens for the long-acting growth hormone pegpesen: A population PK/PD modeling approach.Journal of endocrinological investigation · 2026Article
- [Early diagnosis and intervention for prepubertal short stature children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Review
- Interpreting IGF-1 in children treated with recombinant growth hormone: challenges during early puberty.Frontiers in endocrinology · 2024Article
- Clinical profiles and molecular genetic analyses of 98 Chinese children with short statures.Frontiers in genetics · 2024Article
- Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency.Journal of the Endocrine Society · 2023Article
- Article
- Important Tools for Use by Pediatric Endocrinologists in the Assessment of Short StatureJournal of clinical research in pediatric endocrinology · 2021Review
- Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency.Frontiers in endocrinology · 2021Review
- Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.Acta bio-medica : Atenei Parmensis · 2020Article
- Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone TherapyJournal of clinical research in pediatric endocrinology · 2019Review
- Growth hormone - past, present and future.Nature reviews. Endocrinology · 2018Review
- Treatment of Pre-pubertal Patients with Growth Hormone Deficiency: Patterns in Growth Hormone Dosage and Insulin-like Growth Factor-I Z-scores.Journal of clinical research in pediatric endocrinology · 2017Article
- Effect of growth hormone treatment on children with idiopathic short stature and idiopathic growth hormone deficiency.Annals of pediatric endocrinology & metabolism · 2017Article
- Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.The Journal of clinical endocrinology and metabolism · 2015Review
- A randomized pilot trial of growth hormone with anastrozole versus growth hormone alone, starting at the very end of puberty in adolescents with idiopathic short stature.International journal of pediatric endocrinology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
CONTEXT AND
objectiveTitrating the dosage of growth hormone (GH) to serum levels of insulin-like growth factor-I (IGF-I) is a feasible treatment strategy in children with GH deficiency (GHD) and idiopathic short stature (ISS). The objective was to assess the dose-sparing effect and theoretical safety of IGF-I-based GH therapy. DESIGN, SETTING AND PATIENTS: This was a post hoc analysis of a previously described 2-year, multicenter, open-label, randomized, outpatient, controlled clinical trial in 172 prepubertal short children [age 7·5 ± 2·4 years; height standard deviation score (HSDS) -2·64 ± 0·61] classified by baseline peak GH levels as GHD (<7 ng/ml) or ISS (≥7 ng/ml).
interventionConventional weight-based dosing of GH (0·04 mg/kg/day) (n = 34) or GH dosing titrated to an IGF-I target of 0 SDS (IGF0T; n = 70) or an IGF-I target of +2 SDS (IGF2T; n = 68).
main outcome measuresChange in HSDS per GH mg/kg/day dose (∆HSDS/GH dose ratio) and proportion of IGF-I levels above +2 SDS at the end of 2 years.
resultsGH dosing titrated to an IGF-I target of 0 SDS was the most dose-sparing treatment regimen for GHD or ISS children (mean±SE ∆HSDS/GH dose ratios 48·1 ± 4·4 and 32·5 ± 2·8, respectively) compared with conventional dosing (30·3 ± 6·6 and 21·3 ± 3·5, respectively; P = 0·02, P = 0·005) and IGF2T (32·7 ± 4·8 and 16·3 ± 2·8, respectively; P = 0·02, P < 0·0001). IGF0T also resulted in the fewest IGF-I excursions above +2 SDS (6·8% vs 30·0% for conventional dosing; P < 0·01).
conclusionsIGF-I-based GH dosing, targeted to age- and gender-adjusted means, may offer a more dose-sparing and potentially safer mode of therapy than traditional weight-based dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.